P
Pankaj Shah
Publications - 2
Citations - 612
Pankaj Shah is an academic researcher. The author has contributed to research in topics: Cardiotoxicity & Chemotherapy. The author has an hindex of 1, co-authored 2 publications receiving 581 citations.
Papers
More filters
Journal ArticleDOI
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
Gerald Batist,Gopal Ramakrishnan,Chandra Sekhar Rao,Aruna Chandrasekharan,John Gutheil,Troy H. Guthrie,Pankaj Shah,Ali Khojasteh,Madhavan Krishnan Nair,Karen Hoelzer,Katherine Tkaczuk,Youn C. Park,Lily W. Lee +12 more
TL;DR: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.
Reduced C ardiotoxicity a nd P reserved A ntitumor E fficacy of L iposome-Encapsu lated D oxorubicin a nd Cyclophosphamide C ompared W ith C onventional Doxorubicin a nd C yclophosphamide i n a R andomized, Multicenter T rial o f M etastatic B reast C ancer
Gerald Batist,Gopal Ramakrishnan,Chandra Sekhar Rao,Aruna Chandrasekharan,John Gutheil,Troy H. Guthrie,Pankaj Shah,Ali Khojasteh,Madhavan Krishnan Nair,Karen Hoelzer,Katherine Tkaczuk,Youn C. Park,Lily W. Lee +12 more
TL;DR: In this paper, the authors evaluated whether Myocet (liposome encapsulated doxorubicin) in combination with cyclophosphamide significantly reduces doxORubicIN cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).